Innocoll Biotherapeutics, a pharmaceutical company focused on the development and commercialization of pharmaceutical technologies, has relocated its headquarters from Newtown Square, Pennsylvania to Princeton, according to an announcement from Avison Young’s New Jersey office.

The new 10,000-square-foot office space at  at 210 Carnegie Center was unveiled last week at a ribbon cutting ceremony with West Windsor Mayor Hemant Marathe, Innocoll CEO Louis Pascarella and Drew Persson, principal of Avison Young.

Persson represented Innocoll in the relocation and expansion. The sublandlord, Labcorp, was represented by CBRE in the negotiations and the landlord, Boston Properties, was represented in-house.

“Innocoll’s relocation and expansion not only speaks to the company’s continued growth and the biopharmaceutical industry’s need for its revolutionary products, but to the value of New Jersey’s local talent pool to office occupiers,” Persson said.

Innocoll’s current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management in an effort to combat the opioid epidemic while simultaneously cutting down recovery time.

Read the full article here.